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DETC-based bacterial cellulose bio-
curatives for topical treatment of 
cutaneous leishmaniasis
Fabiana S. Celes1, Eliane Trovatti2,3, Ricardo Khouri1, Johan Van Weyenbergh4, 
Sidney J. L. Ribeiro2, Valeria M. Borges1, Hernane S. Barud2,3 & Camila I. de Oliveira1,5
The treatment of leishmaniasis still relies on drugs with potentially serious adverse effects. Herein, we 
tested a topical formulation of bacterial cellulose (BC) membranes containing Diethyldithiocarbamate 
(DETC), a superoxide dismutase 1 inhibitor. Leishmania-infected macrophages exposed to BC-
DETC resulted in parasite killing, without pronounced toxic effects to host cells. This outcome was 
associated with lower SOD1 activity and higher production of superoxide and cytokine mediators. 
Topical application of BC-DETC significantly decreased lesion size, parasite load and the inflammatory 
response at the infection site, as well as the production of both IFN-γ and TNF. Combination of topical 
BC-DETC plus intraperitoneal Sbv also significantly reduced disease development and parasite load. The 
leishmanicidal effect of BC-DETC was extended to human macrophages infected with L. braziliensis, 
highlighting the feasibility of BC-DETC as a topical formulation for chemotherapy of cutaneous 
leishmaniasis caused by L. braziliensis.
Leishmaniasis is a widespread group of parasitic diseases caused by protozoa of the genus Leishmania. Currently, 
about 12 million people are at risk of leishmaniasis and there are an estimated 1.5–2 million new cases each year1. 
There are two main clinical manifestations: Visceral Leishmaniasis (VL), affecting mainly the spleen and liver, 
and Cutaneous Leishmaniasis (CL), affecting the skin. CL caused by Leishmania braziliensis is distinguished 
from other leishmaniasis by its chronicity, latency and tendency to metastasize in the human host2. Brazil along 
with nine other countries account for 70–75% of the global CL incidence3. First choice drugs for leishmani-
asis chemotherapy are pentavalent antimonials (Sbv) [Meglumine Antimoniate (Glucantime®) and Sodium 
Stibogluconate (Pentostam®)]4 which are significantly toxic and with reported drug resistance5. Amphotericin B6 
and Miltefosine7 are also limited with regards to toxicity, cost and/or time of treatment, reinforcing the need for 
new chemotherapeutic alternatives.
Dysregulation of the Superoxide Dismutase 1 (CuZnSOD/SOD1) - superoxide axis has been identified as 
key problem in CL8 and SOD1 plasma levels can predict therapeutic failure in CL caused by L. braziliensis9. 
Pharmacological inhibition of CuZnSOD/SOD1 with Diethyldithiocarbamate (DETC), a copper chelator that 
targets SOD110, significantly reduced Leishmania infection in vitro8 as a result of increased superoxide levels. 
In vivo, intraperitoneal injection of DETC inhibited CL development in L. braziliensis-infected mice11, indicating 
the feasibility of treating CL by targeting SOD1-associated pathways.
In the present work, we explored a topical formulation for CL treatment consisting of bacterial cellulose (BC) 
membranes loaded with DETC. BC membrane is a nanomaterial produced by bacteria in the form of a gel-like 
membrane12,13 it has high water content (about 99%) and displays good mechanical properties14. BC is biocom-
patible, permeable to gas and liquids, it improves wound and burn healing and is easily managed by the patient 
(rev. in ref. 15). Never dried BC’s nanometric dimension and liquid absorption/release capability enable its use as 
a support for drug release in topical systems16,17, mainly because of its membranous form. We show that dried BC 
membranes loaded with DETC (BC-DETC) significantly reduced L. braziliensis-infection rate in vitro and lesion 
development in vivo. Combination of topical BC-DETC with intraperitoneal Sbv was even more effective against 
CL development, indicating the feasibility of such approach.
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Results
Characterization of BC-DETC membranes by SEM and FTIR. Initially, we characterized the con-
trol (empty) and BC-DETC membranes by SEM. Micrographs showed the characteristic tridimensional fibrillar 
network of bacterial cellulose (Fig. 1). Upon addition of DETC (3.5 μ g DETC/cm2), the network does not show 
the presence of DETC aggregates, indicating homogeneous dispersion without irregular precipitation during 
compound adsorption onto BC matrices. Also, an increasing density of the DETC was observed in BC networks 
when higher concentrations of DETC were used (35 μ g/cm2 and 350 μ g/cm2) (Fig. 1). BC-DETC FTIR spec-
tra obtained with different concentrations of DETC showed a superposition of both BC and DETC spectrum 
(Supplementary Figure 1). We observed a shift of two peaks of DETC, from 1673 and 1616 cm−1 to 1739 and 
1630 cm−1, respectively which suggests the non-bonded interaction of oxygen form hydroxyl groups of BC with 
sulfur from DETC.
BC-DETC membranes reduce the parasite load in a dose-dependent manner. Exposure of 
murine macrophages to BC-DETC at 3.5 or 35 μ g DETC/cm2 did not change cell viability whereas BC-DETC 
at 350 μ g DETC/cm2 reduced cell viability by 40% (Supplementary Figure 2). To evaluate the killing potential, 
L. braziliensis-infected BMDM were exposed to BC-DETC. BC-DETC (3.5 and 35 μ g DETC/cm2) significantly 
decreased the number of infected macrophages (Fig. 2A) and the number of amastigotes per 100 cells (Fig. 2B). 
Exposure to empty BC (0 μ g DETC/cm2) did not decrease L. braziliensis infection in a significant manner (Fig. 2A 
and B). To confirm that DETC compromised parasite viability, intracellular parasite survival was quantified by 
transformation of amastigotes into proliferating promastigotes in Schneider’s medium, as described8. L. brazil-
iensis promastigotes were significantly reduced following exposure of infected BMDM to BC-DETC (Fig. 2C) but 
not upon exposure to empty BC. These results indicate that DETC is acting on infected macrophages, leading to 
parasite killing.
BC-DETC reduces SOD activity and increases superoxide and cytokine release in L. 
braziliensis-infected murine macrophages. SOD1 catalyzes the dismutation of superoxide into oxygen 
and hydrogen peroxide and DETC is a copper chelator that inhibits SOD1, thereby increasing superoxide levels. 
We therefore evaluated SOD1 activity and superoxide production in L. braziliensis-infected macrophages exposed 
to BC-DETC. SOD1 activity was significantly decreased in BC-DETC-exposed cells (Fig. 3A) whereas superoxide 
levels were significantly increased in this same condition (Fig. 3B), compared to unexposed controls. Such results 
are in line with the observed parasite killing upon exposure to BC-DETC (Fig. 2). In the presence of BC-DETC, 
TNF, IL-6, IL-10 and CCL2 levels were significantly increased (Fig. 3C–F, respectively), an effect not observed in 
cultures exposed to empty BC (Fig. 3C–F). These results suggest that parasite killing is resulting from increased 
superoxide levels and SOD1 inhibition by DETC. Increased cytokine production appears to be a side-product of 
parasite killing by DETC-exposed cells.
Topically-applied BC-DETC reduces the lesion size and the parasite load in vivo. Next, we 
tested the effect on BC-DETC in vivo, employing an experimental model of CL18. Mice were inoculated with 
Figure 1. Scanning electron micrographs of bacterial cellulose membrane (BC) and BC membranes 
containing DETC. All images were obtained on 30,000X magnification.
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L. braziliensis and three weeks later, BC-DETC (loaded at 35 and 350 μ g DETC/cm2) was applied to cutaneous 
lesions, membranes were changed three times a week. BC-DETC loaded with 35 μ g DETC/cm2 did not signif-
icantly reduce ear thickness in infected mice whereas treatment with 350 μ g DETC/cm2 induced a significant 
effect two weeks after the onset of treatment (five weeks after parasite inoculation) (Supplemental Figure 3). 
Additionally, we did not observe differences comparing mice treated with emtpy BC. Based on this, control mice 
were treated with empty BC in subsequent experiments. Overall, topical application of BC-DETC (at 350 μ g 
DETC/cm2) significantly decreased ear thickness, an effect not observed in control mice (treated with empty BC) 
(Fig. 4A). In control mice, dermal lesions were visually larger (at six weeks after infection). Histopathological 
examination of tissue sections showed the presence of an intense inflammatory infiltrate, containing epidermal 
hyperplasia and ulcerated areas, characteristic of CL lesions19 (Fig. 4A). On the contrary, ears of animals treated 
Figure 2. Dose-dependent effect of BC-DETC on L. braziliensis-infected macrophages. Macrophages were 
infected and exposed to empty BC or to BC-DETC (3.5 or 35 μ g/cm2). Cells were assessed for (A) the percentage 
of infected macrophages and (B) the number of amastigotes per 100 macrophages. (C) The number of viable 
parasites was evaluated by culture in Schneider medium, free of BC-DETC. Data are from a representative 
experiment performed in quintuplicate. *p < 0.05, ***p < 0.001.
Figure 3. BC-DETC treatment reduces SOD activity and modulates cytokine release in L. braziliensis-
infected macrophages. Macrophages were infected and exposed to empty BC or to BC-DETC (3.5 or 35 μg/cm2). 
(A) SOD activity, (B) superoxide, (C) TNF, (D) IL-6, (E) CCL2/MCP-1 and (F) IL-10 levels were evaluated 
after 48 hours. Data are from a representative experiment performed in quintuplicate. *p < 0.05, **p < 0.01, 
***p < 0.001.
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with BC-DETC showed smaller lesions and a mild cellular infiltrate and less hyperplasia (Fig. 4A). At seven 
weeks, lesions began to heal spontaneously in both BC-DETC and control groups, as previously described for this 
experimental model of CL18. Disease burden, calculated by the area under the curve (AUC) obtained for mice 
treated with BC-DETC or with empty BC was also significantly different (Fig. 4B), confirming that BC-DETC 
inhibits lesion development, in vivo. Moreover, topical application of BC-DTEC significantly decreased the para-
site load (Fig. 4C), measured six weeks after parasite inoculation (three weeks after the onset of treatment), differ-
ently from control mice (treated with empty BC). At this same time point, however, parasite load within draining 
lymph nodes was similar for BC-DETC and control mice (Fig. 4D). These data demonstrate that topically applied 
BC-DETC controls lesion development and reduces the parasite load at the lesion site.
IFN-γ and TNF are associated with the inflammatory nature of the CL lesion20 so we also addressed the 
cellular immune response in mice treated with BC-DETC. Mice were euthanized at different time points during 
the treatment period and the recall response of lymph node cells was evaluated. IFN-γ , TNF, IL-10 and IL-4 lev-
els were overall higher in control mice compared to BC-DETC-treated mice (Fig. 5A) (Supplemental Figure 4). 
At six weeks post infection (three weeks after the onset of treatment), the pattern of cellular response in 
BC-DETC-treated mice was clearly distinct from that observed in control mice (Fig. 5A), corroborating the phe-
notypic differences observed earlier regarding lesion size and parasite load (Fig. 4A). At this time point, levels 
of IFN-γ , TNF and IL-4 were significantly lower in mice treated with BC-DETC (Fig. 5B), a finding than can be 
associated with the milder inflammatory reaction observed (Fig. 4A). Collectively, our results show that topi-
cal application of BC-DETC reduces CL lesions and parasite load and, in parallel, modulates the inflammatory 
response.
Combination therapy. The drugs of first choice for the chemotherapy of leishmaniasis are pentavalent 
antimonials (Sbv). We therefore investigated whether a combination treatment consisting of topical BC-DETC 
and intraperitoneal Sbv would result in a more effective control of experimental CL. Mice were infected with 
L. braziliensis and treated with BC, BC-DETC, Sbv or BC-DETC plus Sbv. Both Sbv alone and BC-DETC alone sig-
nificantly reduced lesion size, observed five and six weeks post infection (Fig. 6A) whereas combination therapy 
consisting of BC-DECT plus Sbv reduced lesion size by approximately 43%, compared to controls. These results 
Figure 4. Topical treatment with BC-DETC controls CL development. Mice were infected with L. braziliensis 
and three weeks later BC-DETC (at 350 μ g/cm2) was applied for three weeks (boxed area). Controls received 
empty BC. (A) Lesion development was measured weekly. Ear sections, obtained six weeks after infection, 
were analyzed by optical microscopy under 20X magnification. (B) Disease burden [shown as Area Under the 
Curves (AUC) depicted in (A)] in mice treated with BC-DETC or empty BC. Parasite load was determined at 
the infection site (C) and at the dLN (D), at six weeks, by limiting dilution analysis. Data are pooled from three 
independent experiments, each performed with four to six mice per group. **p < 0.01.
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were corroborated by the AUC analysis: disease burden in BC-DETC, Sbv and BC DETC plus Sbv were signifi-
cantly reduced compared to control mice (treated with empty BC) (Fig. 6B). Parasite load was also significantly 
reduced in the three experimental groups compared to controls (Fig. 6C). Combination treatment significantly 
reduced parasite load in the draining lymph nodes (Fig. 6D), an effect also observed in mice treated with Sbv 
alone. Combination therapy consisting of topical BC-DETC plus Sbv reduces CL development in vivo; however, 
we did not observe significant differences compared to treatment with either BC-DETC alone or Sbv alone.
BC-DETC membranes promotes parasite killing in human macrophages infected with L. braziliensis. 
We extended our investigation to human macrophages infected with L. braziliensis. In these cells, the IC50 of 
BC-DETC was determined at 284.9 μ g DETC/cm2. Upon exposure of human macrophages infected with L. bra-
ziliensis to BC-DETC (IC50), we observed a 50% reduction in the percentage of infected cells (Fig. 7A) and a 
significant reduction in the number of amastigotes (Fig. 7B), compared to unexposed control cultures. Presence 
of Apocynin, an anti-oxidant, reversed the killing effect, confirming that microbicidal action of BC-DETC on 
human infected macrophages is dependent on superoxide (Fig. 7A and B). Representative photographs con-
firmed the reduction in intracellular parasites in BC-DETC-exposed macrophages whereas control cultures per-
formed with empty BC or with BC-DETC + Apocynin showed the opposite effect (Fig. 7C). Finally, the CC50 of 
BC-DETC was calculated at 2,312 μ g/cm2. The selectivity index of BC-DETC was established at 8.11.
Discussion
The main control strategy against leishmaniasis consists on treatment with leishmanicidal drugs that, despite their 
long use, present problems regarding cost, toxicity, side effects, and increasing number of resistance reports21. We 
previously demonstrated that intraperitoneal injection of DETC is a therapeutic alternative for CL chemotherapy8,11. 
Herein we extended on these findings employing a topical formulation consisting of BC membranes loaded with 
DETC. The use of a topical treatment poses advantages such as easy application, less side effects and lower toxicity 
due to lower dosage, therefore increasing adherence to treatment and probability of success.
BC is biocompatible and biodegradable22 and, as such, has been applied in different contexts23–25. SEM showed 
that DETC penetrated and dispersed onto BC surface, resulting in membranes with elevated flexibility and homo-
geneous distribution, corroborating results obtained in with ibuprophen26, diclofenac27 and caffeine28 -loaded 
BC. FTIR spectra showed absence of novel peaks during BC-DETC preparation. The DETC peaks at position 
1673 and 1616 cm−1 were shifted to 1739 and 1630 cm−1, respectively, and these chemical interactions suggest the 
formation of a controlled release system in which the free molecules are rapidly released by diffusion through the 
membrane, while molecules that interact with the membranes are slowly released.
Figure 5. BC-DETC treatment modulates the cellular recall response. Mice were infected and three weeks 
later BC-DETC (at 350 μ g/cm2) was applied for three weeks. Controls received empty BC. Draining lymph 
nodes were re-stimulated in vitro and cytokines were quantified by ELISA. (A) Heat map depicting cytokine 
production, colored to indicate levels. Insert shows data for individual mice at six weeks. (B) Cytokine levels 
detected in culture supernatants, at six weeks. Data are from a representative experiment performed with six 
mice per group. *p < 0.05.
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Exposure of murine macrophages to BC-DETC did not result in cytotoxicity, at the concentrations of 3.5 and 
35 μ g/cm2 corroborating earlier findings29–31 and supporting the biocompatibility of BC. Macrophages infected 
with L. braziliensis and exposed to BC-DETC displayed a significantly decreased infection rate, which was asso-
ciated with down regulated SOD activity and increased superoxide levels. These results are in agreement with our 
earlier finding that SOD-1 activation contributes with Leishmania survival whereas SOD1 inhibition by DETC 
promotes parasite killing in a superoxide-dependent manner8,11. L. braziliensis-infected macrophages exposed 
to BC-DETC displayed a significant increase in cytokine (TNF, IL-6 and IL-10) and chemokine (MCP-1/CCL2) 
release. TNF activates macrophages to kill Leishmania32; it also induces CCL233 and ROS release34,35. ROS but 
not nitric oxide (NO) has been associated with killing in L. braziliensis-infected human monocytes36. Herein, 
we did not detect NO upon exposure of infected macrophages to BC-DETC (data not shown). We suggest 
that, in vitro, DETC-mediated SOD1 inhibition increased superoxide levels, synergizing with an elevation in 
macrophage-activating cytokines that collectively contribute to L. braziliensis elimination.
We then evaluated the therapeutic potential of BC-DETC in vivo. Topical application of BC-DETC L. braziliensisi 
lesions significantly decreased ear thickness and parasite load at the infection site but not within draining lymph 
nodes. Treatment with 17-AAG, a HSP90-specific inhibitor, also did not decrease parasite load in distal sites 
despite having a clear leishmanicidal effect at the lesion site37. In experimental L. braziliensis infection, para-
sites persist within draining lymph nodes, possibly resulting from the presence of regulatory T cells (Tregs) that 
secrete IL-10 and counteract effector T cells38. In L. major infection, Tregs (CD25 + Foxp3+ T cells) regulate 
the Leishmania-specific effector response. A dynamic equilibrium between Tregs and effector cells is estab-
lished maintaining long-term persistence of low numbers of parasites in the skin [(rev. in ref. 39]. This outcome 
is advantageous for the parasite since the host is capable of transmitting Leishmania to sand flies40, but is also 
induces long lived immunity against re-infection, an advantage to the host. Indeed, complete elimination of the 
parasites reduces resistance to infection41,42. We speculate that the inability of BC-DETC to reduce parasite num-
bers in draining lymph nodes associated with the presence of Tregs during L. braziliensis infection38,43 could 
have a similar impact. Importantly topical BC-DETC performed as well as intraperitoneal injection of DETC11, 
Figure 6. Efficacy of topical BC-DETC and intraperitoenal Sbv combined therapy in L. braziliensis 
infection. Mice were infected and three weeks later were treated with topical BC-DETC (at 350 μ g/cm2), 
intraperitoneal Sbv (100 mg/kg/day) or both. Controls received empty BC. (A) The course of lesion size 
development was measured weekly. (B) Disease burden [shown as Area Under the Curves (AUC) depicted in 
(A)] for each group. Parasite load was determined at the infection site (C) and at the dLN (D), 6 weeks after 
infection, by limiting dilution analysis. Data are from a representative experiment performed with twelve mice 
per group. *p < 0.05; **p < 0.01; ***p < 0.001.
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with respect to decreasing lesion size and parasite load at the infection site. Similar results were obtained with 
Dissulfiram, a carbamate derivative similar to DETC, and L. major-infected mice44 and Dissulfiram in combina-
tion with kanamycin and amoxicillin showed an additive effect against L. major promastigotes45. These findings 
reinforce the potential of a DETC-based topical formulation for CL treatment.
Topical application of BC-DETC significantly decreased in IFN-γ and TNF production by dLN cells, com-
pared to controls, in accordance with the milder inflammatory reaction observed in situ. We suggest that, in vivo, 
DECT-mediated SOD1 inhibition increased superoxide levels, leading to parasite killing and thus diminishing 
the inflammatory stimulus (reflected in lower IFN-γ and TNF levels). Although IFN-γ and TNF are key mole-
cules for macrophage activation and leishmania killing, excessive inflammation is related to tissue damage and 
the development of more severe clinical manifestations of CL20,46,47. In accordance, Dissulfiram suppressed TNF, 
NO and PGE2 release after LPS injection48 and it also significantly inhibited the release of LPS-induced metallo-
proteinases and TNF via an increase in superoxide release49.
Given that treatment options for CL are currently limited and that the number of refractory cases has 
increased; topical application of BC-DETC can be envisaged as part of a combination treatment. Advantages of a 
combination treatment include increased efficacy, less drug resistance, lower drug dosage and a general decrease 
in side effects50. Combination therapy can also hinder the appearance of monotherapy-resistant parasites51 and, 
as such, it is being pursued in recent studies using Tamoxifen as an alternative to treat CL52,53. Herein, topical 
BC-DETC was as effective as intraperitioneal Sbv when we evaluated lesion development and parasite replication 
at the infection site.
Lastly, exposure of L. braziliensis-infected cells to BC-DETC (IC50) decreased the parasite load in a significant 
manner. Apocynin reverted this effect confirming the superoxide-dependent parasite killing in human cells exposed 
to BC-DETC. To date, clinical studies employing topical formulations have demonstrated efficacy in CL caused by 
L. major54,55 and L. panamensis56,57 but similar trials have not performed in areas of CL caused by L. braziliensis. 
Given the current limitations regarding leishmaniasis chemotherapy, BC-DETC topical bio-curative58, described 
in the present work, is an effective and translatable addition to the existing chemotherapies currently available 
for CL.
Methods
Ethics statement. Female BALB/c mice (6–8 weeks of age) obtained from the animal facility at Instituto 
Gonçalo Moniz, FIOCRUZ were maintained under pathogen-free conditions. All procedures were done 
following the local Ethics Committee on Animal Care and Utilization recommendations (CEUA IGM-
FIOCRUZ-L-001/12). All experimental protocols were approved by CEUA IGM-FIOCRUZ. Peripheral Blood 
was obtained from healthy individuals (n = 6) recruited in the city of Salvador (Bahia state, Brazil). This research 
was conducted with the approval of the ethical committee of Instituto Gonçalo Moniz (IGM), Fundação Oswaldo 
Cruz (FIOCRUZ) (Salvador, Bahia, Brazil; CEP 177/2008) and Comissão Nacional de Ética em Pesquisa 
(Brazilian National Ethics Committee, Brazil). All methods were performed in accordance with the guidelines 
Figure 7. BC-DETC leishmanicidal effect on human macrophages infected with L. braziliensis. 
Macrophages were infected and were exposed to BC-DETC (IC50) (284.9 μ g DETC/cm2) in the presence or 
absence of apocynin (APO) (20 μ M). Cells were assessed for (A) the percentage of infected macrophages  
(A and B) for the number of amastigotes per 100 macrophages. (C) Representative photomicrographs of 
cultures shown in (A and B). Data are presented individually. *p < 0.05, **p < 0.01.
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and regulations determined by CEP. Written informed consent was obtained from each participant. No minors 
participated in the study.
Preparation of Bacterial Cellulose membranes containing DETC (BC-DETC). Bacterial Cellulose 
(BC) membranes were produced as described17: wet bacterial cellulose membranes were obtained from cultiva-
tion of Gluconacetobacter hansenii (strain ATCC 23769). Cultures were incubated for 96 h at 28 °C in tray- con-
taining medium (glucose 50 gL−1, yeast extracts 4 gL−1, anhydrous disodium phosphate 2 gL−1, heptahydrated 
magnesium, sulphate 0.8 gL−1 and ethanol 20 gL−1). After three days of incubation never-dried hydrated BC 
membranes were obtained. BC membranes were washed in 1% NaOH at 70 °C to remove bacteria and rinsed 
several times in water, until a neutral pH was reached. Membranes were weighed and water mass (~50%) was 
removed by pressure. Purified BC membranes (25 cm2 disks) were used for DETC incorporation. DETC (D3506, 
Sigma) solutions (87.5 ug/mL, 875 μ g/mL and 8,759 μ g/mL) were prepared and 1 mL of each DETC solution was 
applied to BC membranes. Samples were incubated for 2 h. BC-DETC membranes were dried at 37 °C in a ven-
tilated oven for 24 hours. Before use, BC-DETC membranes (loaded with the equivalent of 3.5, 35 and 350 μ g 
DETC/cm2) were cut in disks (4 mm diameter) and sterilized before use by ultraviolet radiation for 15 minutes.
Physical characterization of BC-DETC membranes. Scanning electron microscopic (SEM) images 
were obtained in a field emission scanning electron microscope (FESEM, JEOL JSM-7500F) after covering sam-
ples with a thin carbon layer.
Viability of murine macrophages exposed to BC-DETC. Bone-marrow derived macrophages 
(BMDM) were seeded at density of 3 × 105 cells per well in 24-well tissue plates. BC-DETC membranes 4 mm 
disks (loaded with 3.5, 35 and 350 μ g DETC/cm2) were placed within cell culture wells. Control cultures were 
incubated in medium alone or with empty BC (0 μ g DETC/cm2). Cells were incubated at 37 °C, 5% CO2 for 48 h. 
Plates were then centrifuged for supernatant removal. The total number of viable cells was estimated by Trypan 
blue exclusion considering 200 cells per well, in at least 5 random fields observed by optical microscopy.
Parasite culture. L. braziliensis promastigotes (strain MHOM/BR/01/BA788)18 were grown in Schneider’s 
medium (Sigma) supplemented with 100 U/ml penicillin, 100 mg/ml streptomycin, and 10% heat-inactivated FBS 
(all from Invitrogen) at 26 °C. Stationary-phase promastigotes were used in all experiments.
Macrophage infection with L. braziliensis and exposure to BC-DETC. BMDM were obtained as 
described above. Cells were resuspended in DMEM medium supplemented with 100 U/ml penicillin, 100 mg/ml 
streptomycin, and 10% heat-inactivated Fetal Bovine Serum (all from Invitrogen) and seeded at a density of 
3 × 105 cells per well in 24-well culture plates. Monolayers received 3 × 106 cellsl L. braziliensis promastigotes and 
were incubated at 37 °C in supplemented DMEM medium for 24 h. Infected macrophages were then washed to 
remove non-internalized parasites. BC-DETC membranes (loaded with 3.5 and 35 μ g DETC/cm2) were placed 
within culture wells and plates were incubated at 37 °C/5% CO2. Control cultures were incubated in medium 
alone or with empty BC (0 μ g DETC/cm2). After 48 hours, cells were extensively washed, fixed and stained with 
hematoxylin and eosin (H&E). The number of infected cells and of intracellular amastigotes were counted by 
optical microscopy in 200 macrophages. Cultures were performed in quintuplicate. Alternatively, infected mac-
rophage were exposed to BC or BC-DETC as described, monolayers were extensively washed and the medium 
was replaced by 0.5 ml of supplemented Schneider medium. Cells were cultured for seven additional days at 26 °C, 
when number of viable promastigotes was determined using hemocytometer.
Quantification of superoxide SOD activity and cytokines in culture supernatants. BMDM were 
seeded at a density of 1 × 106 cells per well in 24-well culture plates and cells were infected with L. braziliensis 
as described above. To determine intracellular SOD1 activity, infected macrophages were exposed to BC-DETC 
membranes (3.5 and 35 μ g DETC/cm2) or to empty BC (0 μ g DETC/cm2), as described. Forty eight hours later, 
cells were homogenized in cold 20 mM HEPES lysis buffer (pH 7.2) containing 1 mM EGTA, 210 mM mannitol, 
and 70 mM sucrose. Preparations were centrifuged at 1500 × g for 5 min at 4 °C and cytoplasmic SOD1 levels were 
measured using Superoxide Dismutase Assay Kit II (Calbiochem), according to manufacturer’s instructions. To 
determine superoxide production, BC-DETC or empty BC were placed within wells containing infected cells 
for 48 h in presence of 0.5 mM hydroxylamine hydrochloride (Acros Organics). Superoxide was quantified in 
culture supernatants using Griess reagent8. Cytokine levels were determined in culture supernatants using the 
mouse inflammatory Cytometric Bead Array (BD Biosciences), following manufacturer’s instructions. Data were 
acquired using a FACSort flow cytometer (Becton Dickinson) and analyzed using FlowJo Software version 7.6.4.
L. braziliensis intradermal infection and therapeutic scheme. BALB/c mice were inoculated intra-
dermally with L. braziliensis promastigotes (105 parasites in 10 μ l of saline) using a 27.5-gauge needle18. Ear thick-
ness (as a surrogate for lesion development) was recorded weekly using a digital caliper (Thomas Scientific). 
Three weeks after parasite inoculation mice were randomly assigned into two groups (mean ear thickness at onset 
of treatment 0,33 mm ± 0,01): one group was topically treated with BC-DETC disks (loaded with 35 and 350 μg 
DETC/cm2) and disks were placed onto developed CL lesions. The control group was treated with empty BC 
(0 μ g DETC/cm2). BC-DETC and empty BC were covered with Tegaderm Film (1624 W 3 M Health Care) and 
membranes were replaced three times a week, for five consecutive weeks. Ear thickness (as a surrogate for lesion 
development) continued to be recorded weekly. Six weeks after infection, parasite load was determined using 
by limiting-dilution analysis, as described previously59. In combination experiments, mice were infected and 
monitored as described. Infected mice were randomly assigned into four groups (mean ear thickness at onset of 
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treatment 0,32 mm ± 0,01). Mice were treated with Sbv (Glucantime®, 100 mg/kg/day, intraperitoneal, five days a 
week, for five weeks) alone, Sbv (i.p.) plus topical BC-DETC, topical BC-DETC or topical empty BC.
Cytokine quantification. To evaluate the cellular immune response in mice infected with BC-DETC-treated 
animals, mice were euthanized at different time points and retromaxillar draining lymph nodes (LNs) were 
homogenized in supplemented DMEM medium. Cells (106/ml) were stimulated in presence of L. braziliensis 
promastigotes (5 parasites: 1 cell) for 24 or 48 hours. Control cultures were left unstimulated. Cytokine levels in 
culture supernatants were determined by ELISA (eBioscience), according tomanufacturer’s instructions.
Human macrophage infection with L. braziliensis and exposure to BC-DETC. Human mono-
cytes were isolated from peripheral blood of six healthy donors through Ficoll gradient centrifugation and plas-
tic adherence. Human macrophages were cultivated in supplemented RPMI medium. After differentiation for 
seven days, cells were re-suspended in supplemented RPMI and seeded at a density of 3 × 105 cells per well in 
24-well culture plates. Monolayers were infected with L. braziliensis (10 parasites:1 cell) for 24 hours. Infected 
macrophages were washed to remove non-internalized parasites and were treated with BC-DETC; control cul-
tures were incubated in medium alone or with empty BC (0 μ g DETC/cm2). Cultures were also performed in the 
presence of BC-DETC and Apocynin, an anti-oxidant (20 μ M) (Sigma). After 48 hours, cells were extensively 
washed, fixed and stained with hematoxylin and eosin (H&E). The number of infected cells and of intracellular 
amastigotes were counted by optical microscopy in 200 macrophages.
To calculate the half-cytotoxic concentration (CC50), non-infected macrophages were exposed to BC-DETC 
at different concentrations (350, 700, 1400, 3500, 7000, 14000 and 21000 μ g DETC/cm2). To calculate the 
half-maximal inhibitory concentration (IC50), infected macrophages were exposed to BC-DETC at different con-
centrations (35, 70, 350, 700 and 1400 μ g DETC/cm2).
Statistical analysis. Data are presented as the median ± interquartile range. To evaluate disease burden in 
mice, ear thickness of mice following challenge was recorded weekly for each individual mouse. The course of 
disease for experimental and control mice was plotted individually. Disease burden was calculated as the Area 
Under the Curve (AUC) obtained for each mouse. Differences among BC-DETC-treated versus control mice were 
tested by Kruskal-Wallis (non parametric) followed by Dunn’s multiple comparison test, for comparisons between 
three or more groups. Comparisons between two groups were performed by Mann-Whitney (non-parametric 
t-test). Analyses were conducted using Prism (GraphPad, V 5.0) and a p ≤ 0.05 was considered significant. An 
unbiased hierarchical cluster analysis using Ward’s method was performed to test whether a combination of 
cytokine levels could differentiate BC and BC-DETC-treated groups Median cytokine values (Log2) measured 
at different time points were calculated for each treatment scheme. Heat maps were built using JMP(V 10.0). 
The half maximal-inhibitory concentration (IC50) of BC-DETC on intracellular L. braziliensis amastigotes and 
the half-maximal cytotoxic concentration (CC50) of BC-DETC for human macrophages were determined from 
a sigmoidal regression of the concentration-responses curves, respectively, using Prism (GraphPad V. 6.0). The 
selectivity index of BC-DETC was calculated as the ratio between the CC50 for human macrophages and the IC50 
for intracellular L. braziliensis amastigotes.
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